Provectus Biopharmaceuticals, Inc.
PVCT
Get informed when a big investor buys or sells
+ FollowMarket Cap$25.22M
Close$
$-0.01
115.1% downside
Current Fair Value
115.1% downsideOvervalued by 115.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $25.22 Million |
|---|---|
| Enterprise Value | $29.27 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.01 |
| Beta | 0.83 |
| Outstanding Shares | 420,279,879 |
Return
| Return on Equity | 83.48% |
|---|---|
| Return on Assets | -972.83% |
| Return on Invested Capital | 42.38% |
Valuation & Multiples
| P/E Ratio | -4.51 |
|---|---|
| PEG | -34.21 |
| Price to Sales | - |
| Price to Book Ratio | -0.06 |
| Enterprise Value to Revenue | 509.22 |
| Enterprise Value to EBIT | -10.36 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.15 |
| Debt to Equity | -0.64 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.05%▲ 0.00% |
|---|---|
| Total Invested | $10,375▲ 1.44% |
| Investors Holding | 5▲ 1.00% |
ESG Score
No data
About Provectus Biopharmaceuticals, Inc.
6 employees
CEO: Mr. Dominic Rodrigues C.F.A. Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult soli...